1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6892E4F3D949D5A3685257E22004FF920
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-launch-support-budget-and-activity-allocation?opendocument
18
19opendocument
2018.207.134.98
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Launch Optimization

Medical Affairs Launch Support: Budget and Activity Allocation

ID: 5355


Features:

8 Info Graphics

7 Data Graphics

60+ Metrics


Pages/Slides: 22


Published: 2015


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from " Medical Affairs Launch Support: Budget and Activity Allocation"

STUDY OVERVIEW

The Medical Affairs function plays a significant role in product launch, especially as a direct link between key decision makers and the organization. Thus, a successful launch requires deep involvement of Medical Affairs.

The success of Medical Affairs involvement in launch is tied, in part, to its resources. Without adequate funding, the Medical Affairs function is challenged to effectively execute all the different activities it is involved with in a new product launch.

Best Practices, LLC undertook this benchmarking study to provide investment benchmarks for Medical Affairs launch support. Leading metrics and insights in the study include average launch investment for product support and Medical Affairs investment allocation.

NOTE: Survey responses are segmented on three criteria - Product’s Projected Peak Annual Revenue, Targeted Physicians and Product’s Launch Year.

KEY TOPICS

  • Medical Affairs Launch Investment
  • Medical Affairs Investment Allocation

SAMPLE KEY METRICS
  • Total Launch Investment for Each Product Supported
  • Average Medical Affairs Launch Investment for Each Product Supported
  • Total and Global Medical Affairs Launch Investment For Each Product Supported
  • Percentage of Total Medical Affairs Launch Investment Allocated to Various Activities
  • Percentage of Total Medical Affairs Launch Investment Allocated to Various Medical Affairs Activities
  • Geographic Span of Responsibility for Entire Benchmark Class

SAMPLE KEY FINDING
  • Change from Non-Launch Mode Period Operations to Pre-launch: We observed a significant MA investment allocation increase in three areas during pre-launch process: Field-Based Medical Teams, Thought Leader Management and Scientific Communications and Publications.


METHODOLOGY

This study engaged 28 executives from 24 leading life sciences companies. Segmentation analysis was key to examining trends and effective practices.

Industries Profiled:
Biotech; Pharmaceutical; Health Care; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Amgen; Pfizer; Onyx Pharmaceuticals; ProStrakan; Merz Pharma; Purdue Pharma; Medunik Canada; Sanofi; Janssen; UCB Pharma; Merck; Upsher-Smith; Insys Therapeutics; Xenoport; Jazz Pharmaceuticals; Astellas; Lundbeck; Axon Pharmaceuticals Bayer; Baxter BioScience; Boehringer Ingelheim; Eisai; Incyte

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.